Andre, Fabrice http://orcid.org/0000-0001-5795-8357
Filleron, Thomas
Kamal, Maud
Mosele, Fernanda
Arnedos, Monica
Dalenc, Florence
Sablin, Marie-Paule
Campone, Mario
Bonnefoi, Hervé
Lefeuvre-Plesse, Claudia
Jacot, William http://orcid.org/0000-0001-7834-061X
Coussy, Florence
Ferrero, Jean-Marc
Emile, George
Mouret-Reynier, Marie-Ange
Thery, Jean-Christophe
Isambert, Nicolas
Mege, Alice
Barthelemy, Philippe
You, Benoit http://orcid.org/0000-0002-3177-8857
Hajjaji, Nawale
Lacroix, Ludovic
Rouleau, Etienne
Tran-Dien, Alicia
Boyault, Sandrine http://orcid.org/0000-0002-2297-6894
Attignon, Valery
Gestraud, Pierre http://orcid.org/0000-0002-3893-9879
Servant, Nicolas http://orcid.org/0000-0003-1678-7410
Le Tourneau, Christophe http://orcid.org/0000-0001-9772-4686
Cherif, Linda Larbi
Soubeyran, Isabelle
Montemurro, Filippo http://orcid.org/0000-0003-4231-2291
Morel, Alain
Lusque, Amelie
Jimenez, Marta http://orcid.org/0000-0002-4233-8478
Jacquet, Alexandra http://orcid.org/0000-0001-6377-2487
Gonçalves, Anthony
Bachelot, Thomas
Bieche, Ivan
Article History
Received: 24 October 2021
Accepted: 3 July 2022
First Online: 7 September 2022
Competing interests
: F.A. received research funding and served as a speaker/advisor (compensated by the hospital) for Pfizer, Roche, Lilly, Daiichi Sankyo, AstraZeneca and Novartis. T.B. received research funding and served as a speaker/advisor (compensated by the hospital) for Roche, Novartis, Pfizer, Seattle Genetics, Lilly and AstraZeneca. M.A. received research funding and served as a speaker/advisor (compensated by the hospital) for Novartis, AstraZeneca, Seattle Genetics, Abvie and Pfizer. M.C. received research funding and served as a speaker/advisor (compensated by the hospital) for AstraZeneca, Novartis, Abbvie, Sanofi, Lilly, Pfizer, Sandoz, ACCORD, G1 Therapeutic, Pierre Fabre Oncology, Servier, Roche, Daiichi and Gilead. F.D. received research funding and served as a speaker/advisor (compensated by the hospital) for Roche, Novartis, Lilly, Pfizer, Eisai, MSD and AstraZeneca. C.L.-P. received research funding and served as a speaker/advisor (compensated by the hospital) for AstraZeneca, Roche and Pfizer. A.G. received research funding and served as a speaker/advisor (compensated by the hospital) for AstraZeneca, Pfizer, Novartis, Roche and MSD. M.-A.M.R. received research funding and served as a speaker/advisor for Pfizer, Novartis, Lilly, Roche, MSD and Myriad. W.J. received research funding and served as a speaker/advisor for AstraZeneca, BMS, Daiichi Sankyo, Eisai, Lilly France, MSD, Novartis, Pfizer and Roche. B.Y. received research funding and served as a speaker/advisor for MSD, AstraZeneca, GSK-TESARO, BAYER, Roche-Genentech, ECS Progastrine, Novartis, LEK, Amgen, Clovis Oncology, Merck Serono, BMS, SEAGEN and Myriad. P.B. served as a speaker/advisor for Roche, BMS, IPSEN, MSD, Bayer, Amgen, Esai, Janssen Cilag, Pfizer, Novartis and Astellas and received honoraria from Seagen. N.H. received research funding from Novartis and Pfizer, and served as a consultant for AstraZeneca, Roche, Novartis and Pfizer. N.I. received research funding and served as a speaker/advisor (compensated by the hospital) for Ipsen and Transgene. J.-C.T. received research funding and served as a speaker/advisor (compensated by the hospital) for Pfizer and AstraZeneca. J.-M.F. received research funding and served as a speaker/advisor for Pfizer and Esai. T.F. consulted for Cellectis (compensated by the hospital). The following authors declared no competing interests: F. Mosele, L.L., G.E., A. Mege, F.C., M.-P.S., I.B., E.R., I.S., V.A., S.B., A. Morel, A.T.-D., A.L., H.B., M.J., A.J., L.L.C., M.K., P.G. and N.S. C.L. participated in advisory boards for MSD, BMS, Merck Serono, GSK, AstraZeneca, Nanobiotix, Roche, Rakuten, Seattle Genetics and Celgene. F. Montemurro received consultancy fees from Roche, AstraZeneca, Daiichi Sankyo, SeaGen, MSD, Eli Lilly, Pierre Fabre and Novartis, and travel grants from Roche.